Amarin Corporation

Amarin Corporation Equity

The The Equity of Amarin Corporation (AMRN) as of Nov 19, 2026 is 459.28 M USD. In the previous year, The Equity was 486.18 M USD — a change of -5.53% (lower).

Equity

459.28 MUSD

YoY

-5.53%

Last updated:

In 2025, Amarin Corporation's equity was 459.28 M USD, a -5.53% increase from the 486.18 M USD equity in the previous year.

The Amarin Corporation Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
152.33 M USD
Jan 1, 2019
608.26 M USD
Jan 1, 2020
627.51 M USD
Jan 1, 2021
667.10 M USD
Jan 1, 2022
595.33 M USD
Jan 1, 2023
552.10 M USD
Jan 1, 2024
486.18 M USD
Jan 1, 2025
459.28 M USD
The Amarin Corporation Equity history
YEAREquityYoY
459.28 MUSD-5.53%
486.18 MUSD-11.94%
552.10 MUSD-7.26%
595.33 MUSD-10.76%
667.10 MUSD+6.31%
627.51 MUSD+3.16%
608.26 MUSD+299.31%
152.33 MUSD-333.99%
-65.10 MUSD+618.70%
-9.06 MUSD-92.99%
-129.19 MUSD+46.06%
-88.45 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Amarin Corporation's Equity

Amarin Corporation's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Amarin Corporation's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Amarin Corporation's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Amarin Corporation's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Amarin Corporation’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Amarin Corporation stock

The Equity of Amarin Corporation is 459.28 M USD in 2025.

The Equity of Amarin Corporation changed from 486.18 M USD to 459.28 M USD, representing a -5.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Amarin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Amarin Corporation

All Key Metrics — Amarin Corporation